Stem-Cell Research
BCR-ABL has distinct biological effects in primary human hematopoietic cells
Published in Gene Therapy Weekly, July 1st, 2004
"The tyrosine kinase activity of p210(BCR-ABL) is essential to its leukemogenic potential, but the role of other functional domains in primary human hematopoietic cells has not been previously investigated. Here we show that infection of normal human CD34+ cord blood (CB) cells with a retroviral vector encoding p210(BCR-ABL) rapidly activates a factor-independent phenotype and autocrine interleukin-3/granulocyte colony-stimulating factor/erythropoietin production in the transduced cells," researchers in Canada report.
"These changes," wrote Y. Chalandon and coworkers, "are...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-07-01)
More Articles from Gene Therapy Weekly
- Drug Resistance
Downregulated Bcl-2 or xIAP enhances the efficacy of breast cancer chemotherapy - Gastroenterology
Aurora-2 is a potential target for the treatment of pancreatic cancer - Genetic Engineering
Administration route shapes the effects of IL-12-expressing dendritic cells - Geriatrics
Plasmid-based hormone therapy could improve disease or age-induced wasting - Vector Development
Folate receptors ensure correct delivery of tumor-selective gene therapy - Awards
Doctor named young investigator of the year by gene therapy society - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
